Slingshot members are tracking this event:

AbbVie's (ABBV) HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ABBV Community voting in process

Additional Information

Additional Relevant Details
Hidradenitis suppurativa, sometimes referred to as "acne inversa" by dermatologists, is a painful, debilitating, chronic inflammatory skin disease estimated to affect 1 – 4 percent of the world's population.1-2 The prevalence of HS among adolescents between the ages of 12 and 17 years is estimated to be 0.09 percent (298 adolescents diagnosed with HS out of 328,634 total adolescents sampled).3 The condition is characterized by inflamed, painful lesions typically located around the armpits and groin, on the buttocks and under the breasts.1-2 HS can have considerable impact on patients' quality of life, physical activities and emotional state.1-2,4 The disease can be challenging to diagnose, with studies showing it can take up to eight years for people with HS to receive an accurate diagnosis.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 14, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Adalimumab, Humira, Chmp Positive Opinion, Hidradenitis Suppurativa, Chronic Inflammatory Skin Disease